论文部分内容阅读
目的观察胺碘酮治疗充血性心力衰竭合并室性心律失常的疗效和安全性。方法96例充血性心力衰竭合并室性心律失常的住院患者随机分为两组,在常规治疗的基础上,治疗组口服胺碘酮,对照组口服倍他乐克,治疗前后评价心功能和心律失常改善情况,观察再入院率,病死率,观察1年。结果治疗组心功能改善和抗心律失常疗效优于对照组,再入院率和病死率低于对照组,差异有显著性。两组的不良反应无差异性。结论胺碘酮治疗充血性心力衰竭合并室性心律失常疗效好,安全性高。
Objective To observe the efficacy and safety of amiodarone in the treatment of congestive heart failure with ventricular arrhythmia. Methods Ninety-six inpatients with congestive heart failure and ventricular arrhythmia were randomly divided into two groups. On the basis of routine treatment, the treatment group received amiodarone orally and the control group received metoprolol orally. Heart function and heart rhythm were evaluated before and after treatment Abnormal improvement, observe the readmission rate, mortality, observed for 1 year. Results The improvement of cardiac function and antiarrhythmic effect in treatment group were better than that in control group, and the readmission rate and mortality rate were lower than those in control group. The difference was significant. There was no difference in adverse reactions between the two groups. Conclusions Amiodarone is effective and safe in the treatment of congestive heart failure with ventricular arrhythmia.